Fairmount Funds, a 10% Owner and Director, Sells Over $300M in Oruka Therapeutics Stock
ORKA has more than doubled off its 52-week low of $10.966.
Summary
A major institutional investor and director, Fairmount Funds, sold over $300 million worth of Oruka Therapeutics common stock, significantly reducing its stake.
Key Events · Ownership and Investor Activity · ORKA
-
Major Stock Sale by 10% Owner/Director
Fairmount Funds Management LLC and its affiliated entities, including Director Peter Harwin, sold 3,553,410 shares of Oruka Therapeutics common stock for $300,014,406.30 at an average price of $84.43 per share.
-
Conversion Preceded Sale
The sale followed the conversion of 42,641 shares of Series B Preferred Stock into 3,553,410 shares of common stock, with no cash consideration for the conversion itself.
-
Significant Stake Reduction
This transaction represents a substantial reduction in the reporting owners' holdings, liquidating approximately 43% of their prior stake in the company.
Analysis · ORKA · Life Sciences
Fairmount Funds Management LLC and its affiliated entities, including Director Peter Harwin, executed a substantial liquidation of their stake in Oruka Therapeutics. The sale of over $300 million in common stock, representing more than 10% of the company's market capitalization and approximately 43% of their prior holdings, signals a significant reduction in conviction from a major institutional investor and board member. This large disposition follows recent positive clinical trial results and a substantial public offering, making the timing of the sale particularly notable.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORKA was trading at $86.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $10.97 to $97.78. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.